### HEMO ORGANIC LIMITED

CIN: - L24231GJ1992PLC018224

Address: - 8-A, Gulnar, Chinar - Gulnar Appt. V V Nagar Road Anand -388001 Email ID: -drdineshpatel@rediffmail.com, Website: - www.hemoorganicltd.com

Date: June 30, 2021

To, BSE Limited PhirozeJeejeebhoy Towers, Dalal Street, Mumbai - 400 001.

Dear Sir,

Sub: Submission of Audited Financial Result of the Company for the quarter and year ended on March 31, 2021 along with Audit Report (Modified Opinion) and Statement on Impact of Audit Qualifications (for Audit Report with Modified Opinion)

Ref: Hemo Organic Limited (Security ID: HEMORGANIC, Security Code: 524590)

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the followings:

- 1. Audited Financial Results for the quarter and year ended on March 31, 2021.
- 2. Statement of Assets and Liabilities
- 3. Cash Flow Statement
- 4. Audit Report on the Audited Financial Results.
- 5. Statement on Impact of Audit Qualifications (for Audit Report with Modified Opinion)

  Kindly take the same on your record and disseminate the same on your website and oblige us.


Thanking You, Yours faithfully,

For, Hemp Organic Limited

Dr. Dinesh Patel Managing Director DIN 00481641

Place: Anand





01/04




| Particulars  | As at 31st<br>March 2021 | Rs. in lakhs) As at 31st March 2020 |
|--|--------------------------|-------------------------------------|
| ASSETS   |                          | WARTER 2020                         |
| Non-current assets   |                          |                                     |
| (a) Property, Plant and Equipment  | 1                        |                                     |
| (b) Capital work-in-progress   | 0.20                     | 0.20                                |
| (c) Intangible assets under development  | 1 1000                   |                                     |
| (d)/Financial Assets   | A Company                | 10.11                               |
| (i) Investments  |                          |                                     |
| (ii) Loans   | 1                        |                                     |
| (iii) Other Financial Assets   |                          | *                                   |
| (e) Deffered Tax Assets  | 14.05                    |                                     |
| (f) Other Non - Current Assets   | 14.05                    | 14.03                               |
| Current assets   |                          |                                     |
| (a) Inventories  | 0.00                     | 6.                                  |
| (b) Financial Assets   | 0.23                     | 0.14                                |
| (i) Trade receivables  | 6.70                     | 6.00                                |
| (ii) Cash and cash equivalents   | 0.44                     | 6.8                                 |
| (iii) Bank balances other than (ii) above  | 0.93                     | 1.80                                |
| (iv) Loans   | 0.93                     | 0.8                                 |
| (v) Other Financial Assets   |                          |                                     |
| (c) Other current assets   | 0.78                     | 0.72                                |
| Total Assets   | 22.22                    |                                     |
|  | 23.33                    | 24.72                               |
| EQUITY AND LIABILTIES  |                          |                                     |
| Equity   |                          |                                     |
| (a) Equity Share capital   | 346.59                   | 346.5                               |
| (b) Other Equity   | (340.01)                 | (335.2                              |
| LIABILITIES  |                          |                                     |
| Non-current liabilities  |                          |                                     |
| (a) Financial Liabilities  |                          |                                     |
| (i) Borrowings   | 3.50                     | 0.2                                 |
| (ii) Other financial liabilities (other than those specified in item (b), to be specified) |                          |                                     |
| (b) Provisions   |                          |                                     |
| (c) Deferred tax liabilities (Net)   |                          |                                     |
| Current liabilities  |                          |                                     |
| (a) Financial Liabilities  |                          | 17/1                                |
| (i) Borrowings   | 3 33 5 3                 |                                     |
| (1) Bollowings   | 8.02                     | 9.5                                 |
| (ii) Trade pavables  | 3.13                     | 2.9                                 |
| (ii) Trade payables  |                          |                                     |
|  | 1.80                     |                                     |
| (ii) Trade payables<br>(iii) Other financial liabilities                                   | 1.80<br>0.30             | 0.0                                 |
| (ii) Trade payables (iii) Other financial liabilities (b) Other current liabilities        |                          | 0.3                                 |

Plate: Anand

Hemo Organic Limited

Dr. Dinesh Patel DIN: 00481641 Managing Director



|          | Cash flow Statement For the year ending on 3                   | 313t march, son  | (Rs. in lakhs)                          |
|----------|--|--|---|
| Sr No.   | Particulars  | Year Ended on 31.03.2021   | Year Ended on 31.03.2020                |
| ,, ,,,,, |  |  |   |
| A.       | Cash flows from operating activites                            | (1.80)   | (2.18                                   |
|          | Net profit before tax  | (4.79)   | (2,10                                   |
|          | Non Cash Income/Expense  | 1 1 10 10 10 10 10 10 10 10 10 10 10 10  |   |
|          | Sundry balances / Excess Liabilities written back              | The same of the sa |   |
|          | Prior Period items - Income Tax                                | 4 70   | (2.18                                   |
|          | Operating profit before working capital changes                | (4.79)   | (2.10                                   |
|          | Net Changes in :-  |  |   |
|          | (Increase)/ decrease in Operating Assets:                      | (0.00)   | 0.07                                    |
|          | - Inventories  | (0,09)   | 66.83                                   |
|          | - Trade Receivables  | 0.17   | 3.16                                    |
|          | - Current Loans  | 1  | 3.10                                    |
|          | - Other Non - Current Assets                                   | 1  | 1.02                                    |
|          | - Other Current Assets   | (0.06)   | 1.02                                    |
|          | Ihcrease/ (Decrease) in Operating Liabilities:                 | 1 1  |   |
| 1        | - Long - Term Provisions                                       |  | (2)16                                   |
|          | Trade Payables   | (1.92)   | (63.16)                                 |
|          | - Short - Term Provisions                                      | 0.05   | *************************************** |
|          | - Liabilty of Borrowing  | 3.30   | (8.10)                                  |
|          | - Other Financial Liabilities                                  | 0.17   | 2.96                                    |
|          | - Other Current Liabilities                                    | 1.80   |   |
|          | Cash generated from operations                                 | (1.37)   | 0.60                                    |
|          | - Income tax paid  |  |   |
|          | Net cash inflow/(outflow) from operating activities (A)        | (1.37)   | 0.60                                    |
|          |  |  |   |
| В.       | Cash flow from investing activites                             |  |   |
|          | - Loans given  |  |   |
|          | - Repayment of Loans & Advances                                |  |   |
|          | - Interest Received  |  |   |
|          | Net cash inflow / (outflow) from investing activities ( B )    |  | •                                       |
|          | Cash inflow/(outflow) from financing activities                | The same of the  |   |
|          | Repayment of short-term borrowings                             |  | ET . HOW                                |
|          | - Proceeds from other long term liabilities                    |  | 7 7 7 7 7 6                             |
|          | - Financial expenses   |  | 17.5                                    |
|          | Net cash inflow / (outflow) used in financing activities ( C ) |  |   |
| •        | Net changes in cash and cash equivalents                       | (1.37)   | 0.60                                    |
|          | * Opening Cash and cash equivalents                            | 2.74   | 2.14                                    |
| -        | Closing Cash and cash equivalents                              | 1.37   | 2.74                                    |
|          | Glosing clish and clish equivalents                            | 4.07   | 2.7.1                                   |
|          | Date: 30/06/2021   | By order of  | the Board                               |
|          | Place : Anand  | Hemo Organ   | ic Limited                              |
|          |  |  |   |
|          |  | Muri   |   |
|          |  | Dr. Dines  | h Patel                                 |
|          | 1  | DIN: 004   |   |
|          |  |  | Diesomo                                 |
|          | · · · · · · · · · · · · · · · · · · ·                          | ivianaging   | 140                                     |
|          | 1.1  |  | 0/                                      |
|          | 03/01  | 4  | drel                                    |

#### Notes:


- 1 The Company operates in a single segment. As per Ind AS 108 on segment reporting prescribed under section 133 of the companies Act, 2013, the same is considered to constitute as single primary segment. Accordingly, the disclosure requirements of Ind AS 108 are not applicable.
- 2 The above standalone financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 30th June, 2021.
- 3 The financial results of the company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the companies Act, 2013 read with relevant rules there under and in terms with regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) regulations 2015 and SEBI circular dated 5th July 2016.
- 4 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities.
- 5 Rrevious period figures have been regrouped and rearranged, whenever considered necessary.
- 6 Estimation uncertainty relating to COVID-19:

The Company has considered internal and certain external sources of information including reliable credit reports, economic forecasts and industry reports up to the date of approval of the financial results in determining the impact on various elements of its financial results. The company has used the principles of prudence in applying judgments, estimates and assumptions including sensitivity analysis and based on current estimates, the company expects to fully recover the carrying amount of trade receivables including unbilled receivables, and investments. The eventual outcome of impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results.

By order of the Board Hemo Organic Limited

> Dr. Dinesh Patel DIN: 00481641 Managing Director

04/04





INDEPENDENT AUDITORS' REPORT on Standalone Annual Financial Results of HEMO ORGANIC LIMITED Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

### TO THE BOARD OF HEMO ORGANIC LIMITED

### **Opinion**

We have audited the accompanying standalone annual financial results of **HEMO ORGANIC LIMITED** ("the Company"), which comprise the Balance Sheet as at 31 March 2021, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

In our opinion and to the best of our information and according to the explanations given to us, except for the matters stated in paragraph basis of qualified opinion the statement:

- is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. gives a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31 March 2021, its loss (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

### **Basis of Qualified Opinion:**

We conducted our audit of the standalone Ind AS financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Our responsibility under those Standards are further described in Auditor's Responsibility for the Audit of the standalone financial statements section of our report. We are independent of the company in accordance of with code of ethics issued by ICAI together with the independence requirement that are relevant to our audit of standalone financial statement under the provisions of the Act and the rule made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the stand alone financial statement except for the following matter:

- 1. We have not been provided with the balance confirmation or any other details for the trade receivable and trade payable shown in the books of accounts.
- 2. We have not been able to verify the transactional documents relating bank statements. Four out of five account are not shown to us for verification. According to the management, the other accounts are dormant and therefore the same have not been collected from bank.

### **Emphasis of Matter**

- 1. We draw your attention to Note 6 the Financial Results which explains the management's assessment of financial impact due to the lock-down and other restrictions and conditions related to the COVID-19 pandemic situation, for which a definitive assessment of the impact in the subsequent period is highly dependent upon circumstances as they evolve.
- 2. The Company has not charged depreciation on the fixed assets during the year and accordingly provision of Indian Accounting Standards relating to depreciation and Deferred Tax Asset / Liabilities have not been followed. The management represented that the amount of depreciation being negligible the same has been not been incorporated.
- 3. The closing stock has been calculated and certified by management only and we have not been provided with the basis of calculation.

## Management's and Those Charged with Governance Responsibilities for the Statement

This Statement has been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit / loss and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI Circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating



effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibility**

Our objectives are to obtain reasonable assurance about whether standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these standalone financial statements.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risk of material misstatement of the standalone financial statements, weather due to fraud or error, design and perform audit procedure responsive to those risk, and obtain evidence that us sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud for one resulting from error, as fraud may involve collusion, forgery, intentional, omission, misrepresentation, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to
  design audit procedure that are appropriate in the circumstances. Under section 143(3)(i)
  of the Act, we are also responsible for expressing our opinion on whether the company
  has adequate internal financial control system in place and the operating effectiveness of
  such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our



- auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The Statement includes the financial results for the quarter ended 31 March 2021, being the balancing figures between the audited figures in respect of the full financial year and the published audited year-to-date figures up to the third quarter of the current financial year, which were subject to audit by us.

Date: 30/06/2021 Place: Ahmedabad

UDIN: 21137390AAAAFA5165

FOR M A A K & ASSOCIATES (Chartered Accountants) Reg No. :135024W

> CA Archit Shah Partner

M.No.: 137390

### HEMO ORGANIC LIMITED

CIN: -1.24231GJ1992PLC018224

Address: - 8-A, Gulnar, Chinar - Gulnar Appt. V V Nagar Road Anand -388001 Email ID: -drdineshpatel@rediffmail.com, Website: - www.hemoorganicltd.com

# STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS

| 1. | SI. |   | ns for the Financial Year ended March 31, 2021                             |  |
|----|-----|---|--|--|
|    | No. | Particulars   | Audited Figures (as<br>reported before<br>adjusting for<br>qualifications) | Adjusted Figures<br>(audited figures after<br>adjusting for<br>qualifications) |
|    | 1.  | Turnover / Total income   | 80,370.28  | 80,370.28  |
|    | 2.  | Total Expenditure   | 5,14,438.34  | 5,14,438.34  |
|    | 3.  | Net Profit/(Loss)   | (4,78,725.33)  | (4,78,725.33)  |
|    | 4.  | Earnings Per Share  | (0.01)   | (0.01)   |
|    | 5.  | Total Assets(Rs. In Thousand)                                       | 2,333.66   | 2,333.66   |
|    | 6.  | Total Liabilities(Rs. In Thousand)                                  | 2,333.66   | 2,333.66   |
|    | 7.  | Net Worth   | 6,58,028.1   | 6,58,028.1   |
|    | 8.  | Any other financial item(s) (as felt appropriate by the management) |  |  |

|   | a. | Details of Audit Qualification:   | <ol> <li>We have not been provided with the balance confirmation or any other details for the trade receivable and trade payable shown in the books of accounts.</li> <li>We have not been able to verify the transactional documents relating bank statements. Four out of five account are not shown to us for verification. According to the management, the other accounts are dormant and therefore the same have not been collected from bank</li> </ol> |
|---|----|---|--|
| 1 | b. | Type of Audit Qualification :<br>Qualified Opinion / Disclaimer of<br>Officen / Adverse Opinion | Qualified Opinion  |
| 3 | 3  | Free Denoy of qualification: Whether appeared first time / repetition / since how long          | Since Long   |

### HEMO ORGANIC LIMITED

CIN: - L24231GJ1992PLC018224

Address: - 8-A, Gulnar, Chinar - Gulnar Appt. V V Nagar Road Anand -388001

Email ID: -drdineshpatel@rediffmail.com, Website: - www.hemoorganicltd.com

|       | continuing  |  |
|-------|---|--|
| d.    | For Audit Qualification(s) where<br>the impact is quantified by the<br>auditor, Management's Views: | NA   |
| e.    | For Audit Qualification(s) where the impact is not quantified by the auditor:                       | No further comments other then audit report  |
| (i)   | Management's estimation on the impact of audit qualification:                                       | The Company is in process of getting balance confirmation from the parties belonging to trade payables and trade receivables.  However, Pending confirmation from trade receivable and trade payable will not affect the financials of the Company.  Further, the accounts which are not shown to auditor are dormant and hence company cannot get the same from bank. |
| (ii)  | If management is unable to estimate the impact, reasons for the same:                               |  |
| (iii) | / /   | Meapplicable   |

For, Hemo' Organic Limited

Dr. Dinesh Patel Chairman & Managing Director

Krushnakant Patel Chairman of Audit Committee

o Organic Limited

For, MAAK& Associates **Chartered Accountants** 

DIN 00481641

C.A Archit Shah PARTNER M. No. 137390

Date: June 30, 2021 Place: Ahmedabad